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Thalidomide as a single agent has been reported to be
efﬁcacious in relapsed or refractory multiple myeloma
(MM) in 30% of patients (1, 2). To improve efﬁcacy and
outcome of thalidomide therapy, clinicians often add
another agent to the monotherapy. The combination with
dexamethasone (Thal⁄Dex) has been reported to increase
the response rate (3–5), but although there have been
several reports evaluating efﬁcacy and toxicity of the com-
bination therapy, the number of patients in the individual
studies is often small and outcomes sometimes obscured
by further addition of other agents like doxorubicine (6).
Also, small sizes of individual studies make the extraction
of additional information like survival outcome and rate
and severity of adverse events unreliable. On the other
hand, the toxicity rate is of particular interest as some
authors report a higher rate of adverse events when
thalidomide is combined with dexamethasone (7) and it
would be important to know if this could possibly
outweigh the beneﬁt of the combination.
We have conducted a review of published studies in a
systematic fashion in order to give an overview of the
existing studies and to determine the pooled response
rate of Thal⁄Dex. We also extracted information on sur-
vival and the toxicity proﬁle, which might aid clinicians
in their application of Thal⁄Dex in the setting of
relapsed⁄refractory MM.
Abstract
Thalidomide monotherapy in relapsed⁄refractory multiple myeloma (MM) has a response rate of 30%. The
combination of thalidomide with dexamethasone (Thal⁄Dex) is expected to improve responses, but it is
unknown if the combination increases the rate of adverse events. Here, we conducted a systematic
review of studies evaluating Thal⁄Dex in relapsed⁄refractory MM. Twelve studies were included, compris-
ing 451 patients. The response rate (CR and PR) was 46% (95% CI 42–51%). Therapy-related toxicity was
comparable to thalidomide monotherapy and included somnolence (26%, 95% CI 22–31%), constipation
(37%, 95% CI 32–42%) and peripheral neuropathy (27%, 95% CI 23–32%). Only venous thromboembo-
lism appeared to occur more often with Thal⁄Dex (5%, 95% CI 3–8%). Thus, using Thal⁄Dex results in an
improved response rate in relapsed⁄refractory MM, with a toxicity rate comparable to thalidomide mono-
therapy.
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Search strategy
MEDLINE (PubMed version) was searched on 15
August 2007 with the combination of the following
terms: thalidomid* AND (myelom* OR plasmocytom*)
AND dexamethason*. Reference lists of all identiﬁed
studies and related reviews were screened. The published
abstracts of the annual meetings of the American Society
of Hematology, the European Haematology Association,
the American Society of Clinical Oncology, the German
and Austrian Society of Haematology and Oncology and
the British Society for Haematology were screened from
1998 to 2006.
Inclusion⁄exclusion criteria
All trials published in the English language were included
that evaluated combination therapy with thalidomide
and dexamethasone in patients with relapsed or refrac-
tory MM and had a clear deﬁnition of complete (CR)
and partial remission (PR). Trials were excluded if they
reported only on patients with plasma cell leukaemia,
solitary or extramedullary plasmocytoma.
Extraction process
A validated structured form was used for an independent
extraction by at least two reviewers for each trial. Dis-
agreements were resolved by consensus with another
reviewer. Reviewers were not blinded to authors or jour-
nals.
Statistical analysis
Descriptive statistics were used and, for the main out-
comes, medians and interquartile range (IQR) or 95%
conﬁdence intervals (95% CI) are reported. Data were
analysed with the statistical package for the social sci-
ences for Windows Software (Release 11.0.1; SPSS Inc.,
Munich, Germany). 95% CI were calculated with conﬁ-
dence interval analysis (version 2.1.1, T. Bryant, South-
ampton, UK). Correlation coefﬁcients were calculated
according to Spearman.
Results
Forty-three trials were identiﬁed of which 18 did not
allow extraction of data. Twenty-ﬁve studies were eligi-
ble, but 13 of them proved to be duplicate or secondary
reports. Therefore, 12 studies entered the ﬁnal analysis
(3–5, 8–16) including altogether 451 patients.
Most studies were unicentric phase II studies and
included a median of 25 patients each. None of them
was a randomised controlled trial. Three studies, includ-
ing 230 patients, were conducted in a multicentric setting.
Publication date was between 2000 and 2007. Character-
istics of included studies are illustrated in Table 1. No
study reported the cumulative dose of thalidomide and
only two studies reported the median dose (300 and
400 mg⁄d respectively), but the start and the target doses
were reported by most studies [median starting dose
200 mg⁄d (IQR 100–200 mg⁄d), median target dose
350 mg⁄d (IQR 200–550 mg⁄d); Table 1]. Table 1 also
depicts dose intensity of dexamethasone in the ﬁrst
month (median 180 mg; IQR 160–290 mg), which was
applied in different schedules: 40 mg⁄d for days 1–4
every month in four studies (181 patients), 40 mg⁄do r
20 mg⁄m
2⁄d for days 1–4 every 3 wk in three studies (66
patients), 12 mg⁄d days 1–4 every 3 wk in one study (12
patients) and 20 mg⁄m
2 days 1–5 every 15 days (47
patients). In two studies with 79 patients, the dexametha-
sone dose (40 mg⁄d days 1–4 or 20 mg⁄m
2⁄d) was
repeated weekly or biweekly in the beginning of the
treatment and then reduced to a monthly schedule. One
study (n = 66) applied 4 mg⁄d dexamethasone in the
ﬁrst month with a quick tapering of 1 mg⁄d⁄wk to a
maintenance dose of 1 mg⁄d.
The median age of the study populations was 63 yr
(IQR 62–65). Six studies provided information as to
whether patients had relapsed or refractory disease.
Here, most patients (n = 185 of a total of 239) had
relapsed disease after prior therapy including high-dose
therapy in at least 33 patients (of ﬁve studies that
reported it). Fifty-four patients suffered from primary
refractory disease.
Table 1 Description of included studies
No.
studies
No. patients
(total 451)
Response rate
CR + PR, %(95% CI)
Size of study (n patients)
5–25 5 82 50 (39–61)
26–46 4 136 48 (40–56)
47–120 3 233 44 (38–51)
Thalidomide starting dose
100 5 250 40 (35–47)
200 5 165 52 (45–60)
400 1 6 83 (44–97)
Thalidomide target dose
100 1 120 52 (43–60)
200 4 156 42 (35–50)
300⁄400 4 84 64 (54–74)
600⁄800 3 91 40 (30–50)
Dexamethasone cumulative dose in ﬁrst month
<200 mg 6 259 45 (39–51)
200–320 mg 4 101 47 (37–56)
>400 mg 2 91 51 (41–61)
Only 11 studies stated a starting dose.
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Group for Blood and Marrow Transplantation (EBMT)
criteria in two studies, one study used the Southwest
Oncology Group (SWOG) criteria. Most studies merely
reported reductions of paraprotein, deﬁning CR by dis-
appearance of paraprotein as determined by immunoﬁx-
ation accompanied by <5% plasma cells in the bone
marrow and PR as a reduction of the paraprotein level
by 50% or 75%. Consequently, we know of 17 (4%)
patients with a CR. Altogether, 209 patients responded
with CR⁄PR, giving a median remission rate of 46%
(95% CI 42–51%, Fig. 1A). In contrast, 39 patients from
nine studies with 260 patients were progressive under
treatment (15%, 95% CI 11–20%) and 44 patients from
eight studies with 222 patients achieved stable disease
(20%, 95% CI 15–26%). An analysis of the inﬂuence of
country, multi- vs. unicentric design and study size
revealed no signiﬁcant difference of response rates. How-
ever, there appears to be a trend towards a better
response with a higher starting dose of thalidomide
(Table 1) and we found a positive correlation between
the starting dose and the response rate (r = 0.7,
P = 0.016, Spearman correlation), but not for the target
dose (P = 0.7). In contrast, there was no signiﬁcant
effect of dose intensity of dexamethasone on the response
rate (P = 0.3).
Four studies reported a median time to response:
1.3 months (44 patients), 2 months in two studies (77
patients) and 4 months (120 patients) respectively. Seven
studies reported event-free survival (EFS): the 1-yr EFS
was 28% in one study, six studies reported a median
EFS with a weighted median value of 8 months (mini-
mum 3.9, maximum 12 months, Fig. 1B). Overall sur-
vival (OS) was reported by seven studies: ﬁve studies
reported a median OS with a weighted median value of
27 months (minimum 13, maximum 38 months); two
studies reported a 1-yr OS of 63% and 83%.
Four hundred and thirty-two patients were evaluable
for any reports of adverse events. Forty patients
(13%, from eight studies with a total of 297 patients)
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Figure 1 (A) Response rates of all included
studies. Each dot indicates the response rate in
one study, the size of the dot corresponds to
the size of the study and the horizontal line
depicts the 95% CI. The vertical line depicts
the overall median and the diamond represents
the 95% CI of the combined response rate. (B)
Event-free survival of the studies that reported
it (n = 6). Each dot indicates the median event-
free survival in one study, the size of the dot
corresponds to the size of the study. The line
depicts the overall median.
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most common adverse events were constipation, neuropa-
thy and somnolence. The rate of thrombo-embolic events
(VTE) was 5% (15 of 308 patients, 95% CI 3–8%, Fig. 2),
which is twice as high as the rate of VTE with thalidomide
monotherapy. We could not identify any relationship
between the dose of either thalidomide or dexamethasone
and the rate of VTE. Most studies did not report any
infectious episodes (3, 4, 8–12, 15). One study reported
one episode of skin infection (5), one reported an episode
of fatal febrile neutropenia (16) and two reported several
episodes of infection [one case of pneumonia, two of
sepsis and one of herpes encephalitis in (13) and 10 respi-
ratory infections, three skin infections and two urinary
tract infection in (14)]. Numbers are too small to draw
any conclusion with regard to an association between the
dexamethasone dose and the rate of infection.
Discussion
This systematic review conﬁrms the improved response
rate of the combination therapy of thalidomide and
dexamethasone in refractory⁄relapsed multiple myeloma.
The pooled data of 12 studies reveal a median response
rate of 46% (95% CI 42–51%), which is a considerable
improvement when compared with thalidomide mono-
therapy, where the median response rate lies at around
30% (1, 2).
Generally, reviews like ours suffer from inconsistencies
amongst studies in reporting adverse events. Here, infor-
mation about toxicity was available on more than 60%
of the whole study population (Table 2), which renders
most observations fairly reliable. Still, a potential report-
ing bias has to be kept in mind when interpreting the
results. Despite the increase in clinical efﬁcacy, the toxic-
ity proﬁle of the combination is very comparable to
monotherapy. The rate of discontinuation was similar to
the rate in monotherapy: here as well as in the previous
review, a discontinuation rate of 13% was found. In con-
trast, constipation and somnolence, which have been
reported to occur in 54% and 56% with thalidomide
alone, occurred considerably less frequently (37% and
26% respectively). We suspect this to be caused by a
lower dose of thalidomide in the combination therapy:
whereas the median target dose in the monotherapy stud-
ies was 800 mg⁄d (1), the median target dose in this
review was 350 mg⁄d. The only adverse event which
occurred more often was the rate of VTE, which was 5%
when combining thalidomide with dexamethasone [vs. 2–
2.7% (1, 2) in monotherapy]. This is nonetheless a low
ﬁgure, particularly when compared with the incidence of
VTE in newly diagnosed MM treated with thalidomide
combinations (14–26%) (17). We hypothesize that this
might be in part caused by a lower tumour burden at
relapse causing less of a procoagulant state. Also, the
surprisingly low ﬁgure might be the result of a more efﬁ-
cient anticoagulation, as most studies were conducted
after 2000, when awareness of the risk of VTE started to
increase. In contrast, studies investigating thalidomide
alone were mostly conducted before 2000 and no antico-
agulation was used. However, most studies of our review
did not report on any anticoagulation and therefore we
can only speculate that the low rate of VTE might be the
result of effective prophylaxis.
Our review shows a higher response rate in those
patients who received a higher dose of thalidomide, sup-
porting similar ﬁndings of studies with thalidomide
monotherapy in relapsed⁄refractory myeloma (18). In
contrast, we could not detect an inﬂuence of dexametha-
sone dose intensity on response rates or toxicity. Cur-
rently, there is ongoing discussion regarding the dose of
dexamethasone in an attempt to optimise efﬁcacy whilst
minimising side effects. The studies reviewed here were
heterogenous with regard to their dexamethasone dosing
schedule, but when analysing the cumulative dose of
dexamethasone in the ﬁrst month we could not ﬁnd a
Table 2 Toxicity of the combination therapy with thalidomide and
dexamethasone
n⁄N % 95% CI
Constipation 140⁄379 37 32–42
Thromboembolic event 15⁄308 5 3–8
Somnolence 93⁄352 26 22–31
Neuropathy 101⁄373 27 23–32
Depression 27⁄265 10 7–14
Discontinuation because
of adverse event
40⁄297 13 10–18
n, events; N, total number of patients for which the incidence of this
adverse effect was reported.
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Figure 2 Rate of venous thromboembolic events (VTE) in those stud-
ies which reported it (n = 7). Each dot indicates the rate of VTE in
one study, the size of the dot corresponds to the size of the study.
The line depicts the overall rate.
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Of note, half of the studies reviewed here had a dexa-
methasone dose intensity similar to the lower-dose arm
in the ECOG study (19) evaluating the thalidomide
derivative lenalidomide combined with high-dose
(480 mg in the ﬁrst month) vs. low-dose (160 mg in the
ﬁrst month) dexamethasone in newly diagnosed multiple
myeloma. Here, patients receiving low-dose
dexamethasone had a signiﬁcant survival beneﬁt. Our
review, while not a randomised study, offers conﬁrma-
tory evidence that lower doses of dexamethasone are also
efﬁcient in the relapsed⁄refractory setting. It is of interest
that the rate of VTE was 6.1% in the ECOG low-dose
arm, comparing well with the 5% in our review of thalid-
omide⁄dexamethasone.
In conclusion, the combination thalidomide⁄dexameth-
asone leads to an increased response rate compared with
thalidomide monotherapy but not to a signiﬁcant increase
in toxicity, suggesting a synergy between these two agents
which allows for more tolerable doses of both substances.
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